{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-001431","form_type":"8-K","ticker":"GKOS","cik":"0001192448","company_name":"GLAUKOS Corp","filed_at":"2024-02-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.583570+00:00","generated_at":"2026-06-05T21:43:44.727269+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Glaukos reports record Q4 net sales $82.4M, up 16% YoY; FY2023 sales $314.7M, up 11%","bullets":["Record Q4 2023 net sales $82.4M, up 16% YoY; glaucoma $60.6M (+15%), corneal health $21.8M (+19%).","Q4 GAAP net loss $36.8M ($0.75/share) vs $31.5M ($0.66) YoY; non-GAAP loss $30.6M ($0.63).","Full-year 2023 net sales $314.7M, up 11% YoY; net loss $134.7M ($2.78/share) vs $99.2M ($2.09) in 2022.","Ended Q4 with $301M cash, equivalents & short-term investments; reaffirmed 2024 net sales guidance $350M-$360M."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-001431","json":"https://secwatch.observer/filing/0001558370-24-001431.json","markdown":"https://secwatch.observer/filing/0001558370-24-001431.md","text":"https://secwatch.observer/filing/0001558370-24-001431.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1192448/000155837024001431/0001558370-24-001431-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1192448/000155837024001431/gkos-20240221x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T21:43:44.727269+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"dc7b68b7bc4c5ff7e5d5504344d6d4a88d55fad2","claim":"GLAUKOS Corp reported the fourth quarter and full year ended December 31, 2023 results: revenue $82.4 million, net income $36.8 million, EPS ($0.75) per diluted share. Guidance reaffirmed.","evidence_excerpt":"disorders and retinal diseases, today announced financial results for the fourth quarter and full year ended December 31, 2023. Key highlights include: ● Record net sales of $82.4 million in Q4 2023 increased 16% year-over-year on a reported basis and 15% year-over-year on a constant currency basis. ● Glaucoma net sales of $60.6 million in Q4 2023 increased 15%","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1192448/000155837024001431/0001558370-24-001431-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2023"},{"label":"Revenue","value":"$82.4 million"},{"label":"Net income","value":"$36.8 million"},{"label":"EPS","value":"($0.75) per diluted share"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}